Pharmacotherapy for uveitis: current management and emerging therapy

Robert J Barry,1 Quan Dong Nguyen,2 Richard W Lee,3 Philip I Murray,1 Alastair K Denniston1,4 1Academic Unit of Ophthalmology, Centre for Translational Inflammation, Research, University of Birmingham, UK; 2Stanley M Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, USA; 3I...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Barry RJ, Nguyen QD, Lee RW, Murray PI, Denniston AK
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/e1686d624d3b41f5a4262cd4b1c30ece
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e1686d624d3b41f5a4262cd4b1c30ece
record_format	dspace
spelling	oai:doaj.org-article:e1686d624d3b41f5a4262cd4b1c30ece2021-12-02T02:43:01ZPharmacotherapy for uveitis: current management and emerging therapy1177-5483https://doaj.org/article/e1686d624d3b41f5a4262cd4b1c30ece2014-09-01T00:00:00Zhttp://www.dovepress.com/pharmacotherapy-for-uveitis-current-management-and-emerging-therapy-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483 Robert J Barry,1 Quan Dong Nguyen,2 Richard W Lee,3 Philip I Murray,1 Alastair K Denniston1,4 1Academic Unit of Ophthalmology, Centre for Translational Inflammation, Research, University of Birmingham, UK; 2Stanley M Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, USA; 3Inflammation and Immunotherapy Theme, National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, University Hospitals Bristol NHS Foundation Trust and University of Bristol, Bristol, UK; 4Department of Ophthalmology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation trust, Birmingham, UK Abstract: Uveitis, a group of conditions characterized by intraocular inflammation, is a major cause of sight loss in the working population. Most uveitis seen in Western countries is noninfectious and appears to be autoimmune or autoinflammatory in nature, requiring treatment with immunosuppressive and/or anti-inflammatory drugs. In this educational review, we outline the ideal characteristics of drugs for uveitis and review the data to support the use of current and emerging therapies in this context. It is crucial that we continue to develop new therapies for use in uveitis that aim to suppress disease activity, prevent accumulation of damage, and preserve visual function for patients with the minimum possible side effects. Keywords: clinical trials, immunomodulatory therapeutic agents, immunosuppression, inflammation, uveaBarry RJNguyen QDLee RWMurray PIDenniston AKDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 1891-1911 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Barry RJ Nguyen QD Lee RW Murray PI Denniston AK Pharmacotherapy for uveitis: current management and emerging therapy
description	Robert J Barry,1 Quan Dong Nguyen,2 Richard W Lee,3 Philip I Murray,1 Alastair K Denniston1,4 1Academic Unit of Ophthalmology, Centre for Translational Inflammation, Research, University of Birmingham, UK; 2Stanley M Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, USA; 3Inflammation and Immunotherapy Theme, National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, University Hospitals Bristol NHS Foundation Trust and University of Bristol, Bristol, UK; 4Department of Ophthalmology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation trust, Birmingham, UK Abstract: Uveitis, a group of conditions characterized by intraocular inflammation, is a major cause of sight loss in the working population. Most uveitis seen in Western countries is noninfectious and appears to be autoimmune or autoinflammatory in nature, requiring treatment with immunosuppressive and/or anti-inflammatory drugs. In this educational review, we outline the ideal characteristics of drugs for uveitis and review the data to support the use of current and emerging therapies in this context. It is crucial that we continue to develop new therapies for use in uveitis that aim to suppress disease activity, prevent accumulation of damage, and preserve visual function for patients with the minimum possible side effects. Keywords: clinical trials, immunomodulatory therapeutic agents, immunosuppression, inflammation, uvea
format	article
author	Barry RJ Nguyen QD Lee RW Murray PI Denniston AK
author_facet	Barry RJ Nguyen QD Lee RW Murray PI Denniston AK
author_sort	Barry RJ
title	Pharmacotherapy for uveitis: current management and emerging therapy
title_short	Pharmacotherapy for uveitis: current management and emerging therapy
title_full	Pharmacotherapy for uveitis: current management and emerging therapy
title_fullStr	Pharmacotherapy for uveitis: current management and emerging therapy
title_full_unstemmed	Pharmacotherapy for uveitis: current management and emerging therapy
title_sort	pharmacotherapy for uveitis: current management and emerging therapy
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/e1686d624d3b41f5a4262cd4b1c30ece
work_keys_str_mv	AT barryrj pharmacotherapyforuveitiscurrentmanagementandemergingtherapy AT nguyenqd pharmacotherapyforuveitiscurrentmanagementandemergingtherapy AT leerw pharmacotherapyforuveitiscurrentmanagementandemergingtherapy AT murraypi pharmacotherapyforuveitiscurrentmanagementandemergingtherapy AT dennistonak pharmacotherapyforuveitiscurrentmanagementandemergingtherapy
_version_	1718402255172927488

Pharmacotherapy for uveitis: current management and emerging therapy

Ejemplares similares